ARGX: argenx SE
Performance
ARGX +12.59%
Watchlist
Select an item
Summary
ARGX at a glance
ARGX returned +12.59% over the past year and +24.49% a year over five years. Its worst drop in that year was -28.58%, smaller than 61% of stocks on Redstone, and its Sharpe ratio of 0.40 beats 45% of stocks on Redstone. It pays no dividends.
Current Drawdown
-9.13%
Rolling Volatility
38.89%
Actions
Metrics
Risk Indicators
Alpha10.07%
Beta0.53x
Sharpe0.40
Sortino0.62
Omega1.08
Calmar0.44
Martin1.22
Profile
About ARGX
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG).
- Sector
- Health Care
- Market cap
- $60.5B
- Listed
- May 2017
- Employees
- 1,863
- Website
- argenx.com
Comparisons